Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice

Clinical and Experimental Allergy

Volumn 34, Issue 8, 2004, Pages 1314-1320

  Quarcoo, D ^a   Weixler, S ^a   Joachim, R A ^a   Stock, P ^a   Kallinich, T ^b   Ahrens, B ^a   Hamelmann, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Charité Humboldt University ^*

Author keywords

Allergy; Asthma; Cytokine; Eosinophils; Immune response modifier; Inflammation; Lung; Mice; Ovalbumin

Indexed keywords

ALLERGEN; CYTOKINE; GAMMA INTERFERON; IMIDAZOLE DERIVATIVE; INTERLEUKIN 12; OVALBUMIN; RESIQUIMOD;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHIL; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTE; MOUSE; MUCUS GLAND; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION; TH2 CELL;

ALLERGENS; ANIMALS; ASTHMA; BIOLOGICAL RESPONSE MODIFIERS; BRONCHI; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; IMIDAZOLES; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; OVALBUMIN; TH2 CELLS;

EID: 4143062435     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02023.x     Document Type: Article

References (45)

1. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
2. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
3. Huang SK, Xiao HQ, Kleine-Tebbe J et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995; 155:2688-94.
4. Hamid Q, Azzawi M, Ying S et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87:1541-6.
5. Hamelmann E, Oshiba A, Schwarze J et al. Allergen-specific IgE and IL-5 are essential for the development of airway hyperresponsiveness. Am J Respir Cell Mol Biol 1997; 16:674-82.
6. Gerhold K, Blumchen K, Bock A et al. Endotoxins prevent murine IgE production, TH2 immune responses, and development of airway eosinophilia but not airway hyperreactivity. J Allergy Clin Immunol 2002; 110:110-6.
7. Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555-9.
8. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999; 162:6284-93.
9. Mingari MC, Maggi E, Cambiaggi A et al. Development in vitro of human CD4+ thymocytes into functionally mature Th2 cells. Exogenous interleukin-12 is required for priming thymocytes to produce both ThI cytokines and interleukin-10. Eur J Immunol 1996; 26:1083-7.
10. Manetti R, Gerosa F, Giudizi MG et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179:1273-83.
11. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995; 182:1527-36.
12. Lack G, Bradley KL, Hamelmann E et al. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. J Immunol 1996; 157:1432-9.
13. Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8.
14. van der Pouw Kraan TC, Boeije LC, de Groot ER et al. Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. J Immunol 1997; 158:5560-5.
15. Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000; 204:64-74.
16. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001; 1:3.
17. Frotscher B, Anton K, Worm M. Inhibition of IgE production by the ImidazoquinolineResiquimod in nonallergic and allergic donors. J Invest Dermatol 2002; 119:1059-64.
18. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 1994; 55:234-40.
19. Weeks CE, Gibson SJ. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994; 14:81-5.
20. Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110:734-9.
21. Wagner TL, Ahonen CL, Couture AM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191:10-9.
22. Gibson SJ, Imbertson LM, Wagner TL et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995; 15:537-45.
23. Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000; 165:5552-7.
24. Bishop GA, Ramirez LM, Baccam M, Busch LK, Pederson LK, Tomai MA. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol 2001; 208:9-17.
25. Tomai MA, Gibson SJ, Imbertson LM et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995; 28:253-64.
26. Hamelmann E, Schwarze J, Takeda K et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156:766-75.
27. Hamelmann E, Oshiba A, Loader J et al. Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med 1997; 155:819-25.
28. Overbergh L, Valckx D, Waer M et al. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 1999; 11:305-12.
29. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179:1485-94.
30. Martin J, Quiroga JA, Navas S, Pardo M, Carreno V. Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine 1999; 11:267-73.
31. Tomkinson A, Cieslewicz G, Duez C, Larson KA, Lee JJ, Gelfand EW. Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. Am J Respir Crit Care Med 2001; 163:721-30.
32. Chin JE, Hatfield CA, Winterrowd GE et al. Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1. Am J Physiol 1997; 272:L219-29.
33. Fukuda T, Fukushima Y, Numao T et al. Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am J Respir Cell Mol Biol 1996; 14:84-94.
34. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 145:3796-806.
35. Van Oosterhout AJ, Fattah D, Van Ark I, Hofman G, Buckley TL, Nijkamp FP. Eosinophil infiltration precedes development of airway hyperreactivity and mucosal exudation after intranasal administration of interleukin-5 to mice. J Allergy Clin Immunol 1995; 96:104-12.
36. Lee JJ, McGarry MP, Farmer SC et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 1997; 185:2143-56.
37. Hamelmann E, Takeda K, Vella AT, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires IL-5 but not IgE or B-cells. Am J Respir Crit Care Med 1999; 21:480-9.
38. Simon HU. Molecular mechanisms of defective eosinophil apoptosis in diseases associated with eosinophilia. Int Arch Allergy Immunol 1997; 113:206-8.
39. Taube C, Duez C, Cui ZH et al. The role of IL-13 in established allergic airway disease. J Immunol 2002; 169:6482-9.
40. Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol 1999; 162:6233-7.
41. Schwarze J, Hamelmann E, Cieslewicz G et al. Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol 1998; 102:86-93.
42. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103:175-83.
43. Randolph DA, Carruthers CJ, Szabo SJ, Murphy KM, Chaplin DD. Modulation of airway inflammation by passive transfer of allergen- specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999; 162:2375-83.
44. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat Immunol 2002; 3:196-200.
45. Broide DH, Stachnick G, Castaneda D et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol 2001; 21:175-82.